Neurocrine Biosciences (NBIX) Assets Average (2011 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Assets Average of $5.1 billion for Q2 2026, up 35.47% year-over-year from $3.8 billion in Q2 2025, and up 7.63% on a QoQ basis from $4.8 billion in Q1 2026.
Neurocrine Biosciences (NBIX) Assets Average (2011 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Assets Average for 16 years, with the latest figure at $5.1 billion in Q2 2026.
- Assets Average for Q2 2026 came in at $5.1 billion, up 35.47% year-over-year; the trailing twelve-month figure through Jun 2026 was $5.1 billion (up 35.47% YoY), and the FY2025 annual result was $4.2 billion, up 19.8% from the prior year.
- Assets Average improved to $5.1 billion in Q2 2026, from $4.8 billion in the prior quarter.
- Over five years, Assets Average peaked at $5.1 billion in Q2 2026 and troughed at $2.1 billion in Q3 2022.
- A 5-year average of $3.3 billion and a median of $3.4 billion in 2024 frame the typical range for Assets Average.
- The widest annual swing landed in 2022, when Assets Average climbed 4.41%; it then soared 42.2% in 2024.
- A 5-year view of Assets Average shows it stood at $2.3 billion in 2022, then soared by 35.18% to $3.0 billion in 2023, then grew by 18.92% to $3.6 billion in 2024, then increased by 22.66% to $4.4 billion in 2025, then rose by 15.38% to $5.1 billion in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $5.1 billion in Q2 2026, $4.8 billion in Q1 2026, and $4.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 5.97 Bn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 4.33 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.13 Bn |
| Mar 31, 2026 | 4.77 Bn |
| Dec 31, 2025 | 4.45 Bn |
| Sep 30, 2025 | 4.08 Bn |
| Jun 30, 2025 | 3.79 Bn |
| Mar 31, 2025 | 3.70 Bn |
| Dec 31, 2024 | 3.63 Bn |
| Sep 30, 2024 | 3.42 Bn |
| Jun 30, 2024 | 3.39 Bn |
| Mar 31, 2024 | 3.36 Bn |
| Dec 31, 2023 | 3.05 Bn |
| Sep 30, 2023 | 2.73 Bn |
| Jun 30, 2023 | 2.49 Bn |
| Mar 31, 2023 | 2.36 Bn |
| Dec 31, 2022 | 2.26 Bn |
| Sep 30, 2022 | 2.07 Bn |
| Jun 30, 2022 | 2.08 Bn |
| Mar 31, 2022 | 2.11 Bn |
| Dec 31, 2021 | 2.04 Bn |
| Sep 30, 2021 | 1.99 Bn |